Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology (2017)
  • Paul M. Barr, University of Rochester
  • Jennifer R. Brown, Harvard University
  • Peter Hillmen, St James's University Hospital
  • Susan O'Brien, Queen Mary University of London
  • Jacqueline Claudia Barrientos, Hofstra University
  • Nishitha M. Reddy, Vanderbilt University
  • Steven Coutre, Stanford University
  • Stephen P. Mulligan, Royal North Shore Hospital
  • Ulrich Jäger, Medical University of Vienna
  • Richard R. Furman, NewYork–Presbyterian Hospital
  • Florence Cymbalista, French Institute of Health and Medical Research
  • Marco Montillo, Catholic University of the Sacred Heart
  • Claire Dearden, The Royal Marsden NHS Foundation Trust
  • Tadeusz Robak, Medical University of Łódź
  • Carol Moreno, Hospital de Sant Pau
  • John Pagel, Cancer Institute
  • Jan Andreas Burger, University of Texas MD Anderson Cancer Center
  • Samuel Suzuki
  • Danelle Frances James, University of California, San Diego
  • John C. Byrd, Ohio State University
Link
Disciplines
Publication Date
January 31, 2017
Citation Information
Paul M. Barr, Jennifer R. Brown, Peter Hillmen, Susan O'Brien, et al.. "Dose adherence and baseline exposure analysis of the ibrutinib 420 mg dose administered to patients with previously treated chronic lymphocytic leukemia (CLL)." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/john-pagel/17/